M. Wenczl

2.0k total citations
15 papers, 705 citations indexed

About

M. Wenczl is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, M. Wenczl has authored 15 papers receiving a total of 705 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in M. Wenczl's work include Lung Cancer Treatments and Mutations (8 papers), Colorectal Cancer Treatments and Studies (7 papers) and Gastric Cancer Management and Outcomes (4 papers). M. Wenczl is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Colorectal Cancer Treatments and Studies (7 papers) and Gastric Cancer Management and Outcomes (4 papers). M. Wenczl collaborates with scholars based in Hungary, Türkiye and Poland. M. Wenczl's co-authors include R. Bugat, Vahur Valvere, Erdem Göker, J. Załuski, Magdolna Dank, Christian Peschel, Laura A. Cisar, Sıddika Songül Yalçın, Carlo Barone and Rodryg Ramlau and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

M. Wenczl

12 papers receiving 680 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M. Wenczl Hungary 6 557 423 198 113 63 15 705
O. Dalesio Netherlands 12 325 0.6× 312 0.7× 237 1.2× 49 0.4× 79 1.3× 25 607
Mao-Chih Hsieh Taiwan 16 453 0.8× 181 0.4× 342 1.7× 216 1.9× 69 1.1× 29 752
M. Castiglione Switzerland 7 186 0.3× 226 0.5× 86 0.4× 34 0.3× 37 0.6× 11 359
Mikayla Quigley United States 9 468 0.8× 298 0.7× 70 0.4× 66 0.6× 78 1.2× 22 597
E Piana Italy 11 340 0.6× 390 0.9× 109 0.6× 65 0.6× 67 1.1× 28 592
Rocco De Vivo Italy 14 172 0.3× 166 0.4× 109 0.6× 23 0.2× 78 1.2× 27 429
Akiko Matsubara Japan 11 194 0.3× 79 0.2× 252 1.3× 76 0.7× 49 0.8× 25 442
Xianglong Zong China 13 252 0.5× 80 0.2× 192 1.0× 110 1.0× 66 1.0× 23 422
Winston Ueno United States 8 113 0.2× 265 0.6× 197 1.0× 15 0.1× 39 0.6× 13 531
Alexandros Papalambros Greece 12 99 0.2× 161 0.4× 140 0.7× 43 0.4× 90 1.4× 25 402

Countries citing papers authored by M. Wenczl

Since Specialization
Citations

This map shows the geographic impact of M. Wenczl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Wenczl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Wenczl more than expected).

Fields of papers citing papers by M. Wenczl

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Wenczl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Wenczl. The network helps show where M. Wenczl may publish in the future.

Co-authorship network of co-authors of M. Wenczl

This figure shows the co-authorship network connecting the top 25 collaborators of M. Wenczl. A scholar is included among the top collaborators of M. Wenczl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Wenczl. M. Wenczl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Eeles, Rosalind A., James P. Morden, Martin Gore, et al.. (2016). Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer. Obstetrical & Gynecological Survey. 71(4). 223–224.
2.
Eeles, Rosalind A., James P. Morden, Martin Gore, et al.. (2015). Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized Trial. Journal of Clinical Oncology. 33(35). 4138–4144. 75 indexed citations
3.
Wee, Wen, Ik‐Joo Chung, István Láng, et al.. (2015). Population pharmacokinetics and exposure-safety relationship of nanoliposomal irinotecan (MM-398, nal-IRI) in patients with solid tumors.. Journal of Clinical Oncology. 33(15_suppl). e13588–e13588. 2 indexed citations
4.
5.
6.
7.
8.
Brodowicz, Thomas, Maciej Krzakowski, Matjaž Zwitter, et al.. (2006). Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial. Lung Cancer. 52(2). 155–163. 256 indexed citations
9.
Peterson, Patrick, Matjaž Zwitter, Maciej Krzakowski, et al.. (2006). Delay in time to worsening of symptoms (TWS) of advanced non-small cell lung cancer (NSCLC) using gemcitabine (gem) maintenance therapy. Journal of Clinical Oncology. 24(18_suppl). 7140–7140. 3 indexed citations
10.
Dank, Magdolna, J. Załuski, C. Barone, et al.. (2005). Randomized phase 3 trial of irinotecan (CPT-11) + 5FU/folinic acid (FA) vs CDDP + 5FU in 1st-line advanced gastric cancer patients. Journal of Clinical Oncology. 23(16_suppl). 4003–4003. 73 indexed citations
11.
12.
13.
Dank, Magdolna, J. Załuski, Carlo Barone, et al.. (2003). 215 A randomized, multinational phase III study in first line metastatic and locally recurrent gastric cancer (MGC): CPT-11 plus 5-fluorouracil (5-FU)/leucovorin (LV) versus cisplatinum (CDDP) plus 5-FU. European Journal of Cancer Supplements. 1(5). S67–S67. 4 indexed citations
14.
15.
Burghardt, Beáta, et al.. (1996). Possible compensation in epidermal growth factor production by saliva in rat. Inflammopharmacology. 4(3). 279–295. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by O. Dalesio Breakdown of academic impact, for papers by Mao-Chih Hsieh Breakdown of academic impact, for papers by M. Castiglione Breakdown of academic impact, for papers by Mikayla Quigley Breakdown of academic impact, for papers by E Piana Breakdown of academic impact, for papers by Rocco De Vivo Breakdown of academic impact, for papers by Akiko Matsubara Breakdown of academic impact, for papers by Xianglong Zong Breakdown of academic impact, for papers by Winston Ueno Breakdown of academic impact, for papers by Alexandros Papalambros
Rankless by CCL
2026